Literature DB >> 25400771

Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.

Caixia Li1, Xiaochen Chen1, Xiao Yu1, Yibei Zhu2, Chao Ma1, Rui Xia2, Jinfeng Ma1, Caihong Gu1, Lu Ye1, Depei Wu1.   

Abstract

T cells immunoglobulin mucin 3 (Tim-3) is an important inhibitory stimulatory molecule, which has been reported to play a vital role in the tumor immune escape and be correlated with clinicopathological prognostic stratification in solid tumor. However, the related research is rare of Tim-3 in non-solid tumor, such as acute myeloid leukemia (AML). In this study, we investigated the expression characteristics of Tim-3 on the peripheral blood T cells of newly diagnosed AML patients and its clinical significance. Peripheral blood was obtained from 36 patients with newly diagnosed AML before intervention, with peripheral blood from 20 cases of healthy volunteers collected as normal control. Expression levels of Tim-3 on the peripheral blood T cells were assayed with flow cytometry. We found that Tim-3 expression on the peripheral blood CD4+ T cells and CD8+ T cells in newly diagnosed AML patients were significantly increased compared with that of normal control. CD4+ T cells/CD8+ T cell ratio (CD4/CD8) of peripheral blood in AML patients was significantly correlated with NCCN high risk group. The higher expression level of Tim-3 on CD4+ T cells in the peripheral blood of AML patients had significant correlation with FLT3-ITD mutation, the higher expression level of Tim-3 on CD8+ T cells in AML patients was significantly correlated with NCCN high risk group. To conclude, our results support the concept that Tim-3 is highly expressed on the peripheral blood T cells of AML patients, and Tim-3 expression significantly correlates with clinicopathological prognostic stratification in AMLTim-3, T cell, acute myeloid leukemia, tumor immune escape, clinicopathological prognostic stratification.

Entities:  

Keywords:  T cell; Tim-3; acute myeloid leukemia; clinicopathological prognostic stratification; tumor immune escape

Mesh:

Substances:

Year:  2014        PMID: 25400771      PMCID: PMC4230106     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

Review 1.  TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Authors:  Gordon J Freeman; Jose M Casasnovas; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

Review 2.  Immunostimulatory monoclonal antibodies for cancer therapy.

Authors:  Ignacio Melero; Sandra Hervas-Stubbs; Martin Glennie; Drew M Pardoll; Lieping Chen
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

3.  HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.

Authors:  Bahareh Vali; R Brad Jones; Ali Sakhdari; Prameet M Sheth; Kiera Clayton; Feng-Yun Yue; Gabor Gyenes; David Wong; Marina B Klein; Sahar Saeed; Erika Benko; Colin Kovacs; Rupert Kaul; Mario A Ostrowski
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

4.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

5.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

6.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

Review 8.  Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.

Authors:  Tsvetelina Pentcheva-Hoang; Emily Corse; James P Allison
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Viral immune evasion due to persistence of activated T cells without effector function.

Authors:  A J Zajac; J N Blattman; K Murali-Krishna; D J Sourdive; M Suresh; J D Altman; R Ahmed
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  23 in total

1.  Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.

Authors:  Gui Cheng; Min Li; Jun Wu; Mei Ji; Cheng Fang; Hongbing Shi; Danxia Zhu; Lujun Chen; Jiemin Zhao; Liangrong Shi; Bin Xu; Xiao Zheng; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

Authors:  Farhad Ravandi; Rita Assi; Naval Daver; Christopher B Benton; Tapan Kadia; Philip A Thompson; Gautam Borthakur; Yesid Alvarado; Elias J Jabbour; Marina Konopleva; Koichi Takahashi; Steven Kornblau; Courtney D DiNardo; Zeev Estrov; Wilmer Flores; Sreyashi Basu; James Allison; Padmanee Sharma; Sherry Pierce; Allison Pike; Jorge E Cortes; Guillermo Garcia-Manero; Hagop M Kantarjian
Journal:  Lancet Haematol       Date:  2019-08-07       Impact factor: 18.959

Review 3.  CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success.

Authors:  Salvatore Fiorenza; Cameron J Turtle
Journal:  BioDrugs       Date:  2021-04-07       Impact factor: 5.807

Review 4.  Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.

Authors:  Hanna A Knaus; Christopher G Kanakry; Leo Luznik; Ivana Gojo
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

5.  Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia.

Authors:  Zi-Jun Xu; Xin-Long Zhang; Ye Jin; Shi-Sen Wang; Yu Gu; Ji-Chun Ma; Xiang-Mei Wen; Jia-Yan Leng; Zhen-Wei Mao; Jiang Lin; Jun Qian
Journal:  Mol Ther Oncolytics       Date:  2022-06-06       Impact factor: 6.311

6.  Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.

Authors:  Toshio Asayama; Hideto Tamura; Mariko Ishibashi; Yasuko Kuribayashi-Hamada; Asaka Onodera-Kondo; Namiko Okuyama; Akiko Yamada; Masumi Shimizu; Keiichi Moriya; Hidemi Takahashi; Koiti Inokuchi
Journal:  Oncotarget       Date:  2017-10-04

7.  Tim-3 Up-regulation in Patients with Gastric Cancer and Peptic Ulcer Disease

Authors:  Mahdieh Naghavi-Alhosseini; Mohsen Tehrani; Abolghasem Ajami; Alireza Rafiei; Tarang Taghvaei; Laleh Vahedi-Larijani; Hadi Hossein-Nataj; Hossein Asgarian-Omran
Journal:  Asian Pac J Cancer Prev       Date:  2017-03-01

Review 8.  CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.

Authors:  Sherly Mardiana; Saar Gill
Journal:  Front Oncol       Date:  2020-05-06       Impact factor: 6.244

Review 9.  Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity.

Authors:  Adam J Lamble; Evan F Lind
Journal:  Front Oncol       Date:  2018-06-13       Impact factor: 6.244

10.  Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

Authors:  Adam J Lamble; Yoko Kosaka; Ted Laderas; Allie Maffit; Andy Kaempf; Lauren K Brady; Weiwei Wang; Nicola Long; Jennifer N Saultz; Motomi Mori; David Soong; Clare V LeFave; Fei Huang; Homer Adams; Marc M Loriaux; Cristina E Tognon; Pierrette Lo; Jeffrey W Tyner; Guang Fan; Shannon K McWeeney; Brian J Druker; Evan F Lind
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.